Carcinoid Syndrome Diarrhea Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Oral Therapy, Somatostatin Analog (SSA) Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals, Clinics, Cancer Research Institutes) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Market Overview

The global carcinoid syndrome diarrhea treatment market is projected to register a healthy CAGR of 13.2% during the forecast period (2023 to 2031). The growing demand for carcinoid syndrome diarrhea treatment in Hospitals, Clinics, and Cancer Research Institutes Applications can be attributed to the carcinoid syndrome diarrhea treatment market share.

Carcinoid syndrome diarrhea is caused by a carcinoid tumor that secretes serotonin and other chemicals into patients’ bloodstream, which causes diarrhea in 80% of incidences. Complications of uncontrolled diarrhea include malnutrition, weight loss, dehydration, and electrolyte imbalance. Signs and symptoms of carcinoid syndrome include flushing of the face, asthma caused by vasoconstriction, debilitating diarrhea, intestinal bleeding, fast heartbeat, shortness of breath, sweating, and unexplained weight gain.

Carcinoid tumors, also known as metastatic neuroendocrine tumors, are rare and slow-developing tumors that predominantly occur in the gastrointestinal tract or lungs. According to the U.S. Food and Drug Administration (FDA), less than 10% of the population with carcinoid tumors develops symptoms of carcinoid syndrome.

Market Dynamics

Global Carcinoid Syndrome Diarrhea Treatment Market Drivers

Increasing Prevalence of Carcinoid Syndrome Diarrhea

The increasing prevalence of carcinoid syndrome diarrhea is a significant factor driving the growth of the treatment market. This rise in prevalence can be linked to various variables, including enhanced diagnostic skills, increased awareness, and an older population. According to the National Organization for Rare Disorders (NORD), approximately 27 persons per million are diagnosed with carcinoid tumors in the United States each year. Only about 10% develop carcinoid syndrome. According to the NCBI, diarrhea occurs in approximately 80% of carcinoid syndrome cases. The diarrhea is frequently described as explosive, non-bloody, and watery by patients. Carcinoid tumors can be fatal, especially if they spread to other regions of the body. Carcinoid tumors have a five-year survival rate of 78-95% and a 10-year survival rate of 77-90%. If the lung carcinoid tumor spreads to the lymph nodes, the five-year survival rate can range between 37 and 80%. 

Additionally, diagnostic technology advancements, like imaging modalities and biomarker identification, have improved the detection and diagnosis of carcinoid syndrome. More precise and early diagnostics aid in identifying those suffering from carcinoid syndrome diarrhea. The growing use of imaging techniques such as CT scans, MRI, and somatostatin receptor scintigraphy has resulted in a higher rate of carcinoid tumors and associated syndrome detection. This has played a role in the observed increase in reported instances. Furthermore, carcinoid tumors and related diseases, such as carcinoid syndrome diarrhea, are frequently identified in people over the age of 50. As the global population ages, the number of persons susceptible to such illnesses grows naturally. Global demographic trends indicate that the world's population is aging. Patients between the ages of 50 and 70 are the most likely to develop carcinoid tumors. However, they grow slowly and are usually identified once the patient is between 55 and 65. Carcinoid tumors are more common in older adults than in younger persons or children. As a result, the rise in carcinoid tumors and the aging population influence the Carcinoid Syndrome Diarrhea Treatment market trend.

Global Carcinoid Syndrome Diarrhea Treatment Market Restraints

Lack of Awareness

The lack of knowledge about carcinoid syndrome and its accompanying symptoms, such as diarrhea, is a significant impediment to the growth of the Carcinoid Syndrome Diarrhea Treatment market. Delays in diagnosis, underreporting of instances, and limited patient and healthcare provider information about potential treatment choices can all come from a lack of awareness. Many people with carcinoid syndrome, particularly those with mild or atypical symptoms like diarrhea, may have delayed diagnosis due to a lack of awareness. The failure to recognize early signs can result in delayed medical intervention and therapy. According to studies, the average period between the development of symptoms and the identification of carcinoid tumors, including instances with diarrhea, can be extended. The average interval between the beginning of symptoms and the diagnosis is more than nine years.

Additionally, patient-related factors, such as a lack of information about the condition, and healthcare provider-related issues, such as a lack of experience with uncommon diseases, can cause delays. Furthermore, the need for more information among healthcare professionals regarding the various manifestations of carcinoid syndrome, combined with its rarity, can contribute to case underreporting. Mild or intermittent diarrhea symptoms may not usually necessitate a complete carcinoid syndrome evaluation.

Global Carcinoid Syndrome Diarrhea Treatment Market Opportunity

Increasing Awareness Campaigns

Investment in disease awareness campaigns and educational activities aimed at healthcare professionals and the general public can improve disease recognition. More cases may be diagnosed as awareness develops, resulting in a greater demand for treatment. Improved disease awareness can positively impact market dynamics by promoting early diagnosis and motivating individuals to seek healthcare. As a result, the demand for Carcinoid Syndrome Diarrhea Treatment may increase. November is also Carcinoid Cancer Awareness Month. The month of November is dedicated to raising awareness about carcinoid cancer, the most frequent type of neuroendocrine tumor. Patient advocacy organizations such as the Carcinoid Cancer Foundation and online platforms dedicated to rare diseases are essential in sharing knowledge on carcinoid syndrome. These organizations frequently conduct awareness campaigns, webinars, and resources for patients and caregivers. According to a Carcinoid Cancer Foundation survey, participation in support groups and access to online resources greatly enhance patient awareness. According to the study, people in such organizations were better aware of their condition and treatment alternatives.

Furthermore, collaborative initiatives within rare disease networks, such as Europe's Reference Networks (ERNs) and the United States National Organization for Rare Disorders (NORD), promote the sharing of best practices, resources, and information regarding rare diseases. EURORDIS (Rare Diseases Europe) stressed the importance of collaborative networks in increasing awareness and access to information regarding rare diseases in a report. These networks allow sharing of expertise and resources, benefiting healthcare providers and patients.

Regional Analysis

North America Dominates the Global Market

The global carcinoid syndrome diarrhea treatment market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.

North America is the most significant global carcinoid syndrome diarrhea treatment market shareholder and is estimated to grow at a CAGR of 13.3% over the forecast period. North America is expected to dominate the global market during the forecast period, owing to the increasing prevalence of carcinoid syndrome diarrhea and high healthcare expenditure in the region. The U.S. FDA is approving new orphan drugs for carcinoid syndrome diarrhea, which is expected to further support market growth in the region. The area includes the United States and Canada, where neuroendocrine tumors, especially carcinoid tumors, are becoming more common. According to the American Cancer Society, around 12,000 cases of carcinoid tumors are detected each year in the United States.

Additionally, according to a study published in the Multidisciplinary Digital Publishing Institute, 20% to 30% of NET patients in the United States had carcinoid disease. According to an article published in Oncotarget, neuroendocrine tumors are common yet have a low incidence. NETs have increased sixfold in the United States over the last few decades. Somatostatin analogs, chemotherapy, and targeted treatments are among the treatment alternatives available. The somatostatin analogs sector leads the market due to their effectiveness in reducing CTS symptoms. Other developing treatment alternatives, such as peptide receptor radionuclide therapy (PRRT), are gaining popularity in North America.

Europe is anticipated to exhibit a CAGR of 13.5% over the forecast period. Europe’s growing geriatric population, coupled with increasing investments in healthcare, is also expected to contribute to the growing demand for carcinoid syndrome diarrhea treatment. The number of individuals aged 65 and over in the European Union (EU) is predicted to rise from 21.1% in 2022 to 31.3% by 2100. According to the World Health Organization (WHO), the population of individuals aged 60 and over in the WHO European Region will increase from 215 million in 2021 to more than 300 million by 2050.

Furthermore, the region includes nations such as Germany, France, Italy, Spain, and the United Kingdom, where neuroendocrine tumors, particularly carcinoid tumors, are becoming more common. Each year, roughly 2,900 persons in the United Kingdom are diagnosed with a neuroendocrine tumor, according to the NHS. Ipsen Biopharmaceuticals, Inc. earned a favorable opinion for Xermelo from the Body for Medicinal Products for Human Use (CHMP), the European Medicines Agency's (EMA) scientific body, in July 2017. This is an essential step in developing novel treatments for neuroendocrine tumors. The European Union has put laws such as the Orphan Medicinal Products Regulation and the Priority Medicines (PRIME) plan in place to encourage the discovery of therapies for rare disorders like CTS. These regulations may aid in driving innovation in CTS management and improving patient access to medicines in Europe. Overall, the European CTS management market will likely expand in the coming years as the disease's prevalence rises and new treatment options become accessible.

Asia-Pacific is expected to observe significant growth in the global market, owing to the increasing prevalence of respiratory diseases such as asthma, COPD, and rhinosinusitis and the high number of smokers in the region. With over 300 million smokers, Asia-Pacific is the world's largest producer and user of tobacco. The Asia-Pacific tobacco market is predicted to expand rapidly in the next few years. China has about 300 million smokers, accounting for approximately one-third of the global population. In China, more than half of adult men are current smokers. China consumes one out of every three cigarettes consumed worldwide. In contrast, the Global Adult Tobacco Survey (GATS 2) found that 28.6% of adults in India aged 15 and overused tobacco in some manner. According to the World Bank Group, smoking prevalence in India’s male population was 20.6% in 2016.

The LAMEA carcinoid syndrome diarrhea treatment market is expected to witness sluggish growth during the forecast period, owing to the poor healthcare infrastructure in Africa, according to carcinoid syndrome diarrhea treatment market insights. However, growing urbanization, improving healthcare infrastructure, and high disposable income in Middle Eastern countries such as UAE, Saudi Arabia, and Kuwait are projected to drive market growth somewhat.

Segmental Analysis

The global carcinoid syndrome diarrhea treatment market is segmented based on treatment type, distribution channel, end-user, and region.

The market is further segmented by treatment type into Chemotherapy, Oral Therapy, and Somatostatin Analog (SSA) Therapy.

Somatostatin Analog (SSA) Therapy accounts for the largest share of the market.

Somatostatin Analog (SSA) Therapy

The SSA therapy sector is expected to hold a significant market share, owing to its excellent efficacy in treating carcinoid syndrome diarrhea. Somatostatin analog therapy entails using medications that replicate the effect of somatostatin, a naturally occurring hormone that blocks the production of several hormones, including those linked to carcinoid syndrome. Injections of SSAs such as octreotide and lanreotide are joint. They function by decreasing the production of hormones that produce symptoms such as diarrhea and flushing, relieving people suffering from carcinoid syndrome. SSAs have an essential role in the medical treatment of carcinoid syndrome diarrhea.

Chemotherapy

Chemotherapy is the use of medications to treat carcinoid syndrome diarrhea by targeting and suppressing cancer cell proliferation. These drugs are frequently delivered intravenously and have a systemic effect on the body. Chemotherapy may be used to decrease tumor growth and treat symptoms associated with carcinoid syndrome in cases where the carcinoid tumors are more aggressive or have migrated beyond their originating site.

By Distribution channels, the market can further bifurcate into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

Hospital Pharmacies generate the most revenue.

Hospital Pharmacies

The hospital pharmacies sector is predicted to account for a significant market share, owing to the expanding number of hospital pharmacies worldwide. Hospital pharmacies are pharmaceutical facilities that are located within hospitals or medical centers. They dispense medications given to hospitalized patients, especially those undergoing chemotherapy or other cancer-related therapies for diseases such as carcinoid syndrome diarrhea.

Furthermore, hospital pharmacies ensure timely access to pharmaceuticals required during hospitalization. They work closely with healthcare teams to ensure the correct distribution and administration of prescription medications, particularly those used to treat carcinoid syndrome.

Retail Pharmacies

Retail pharmacies, sometimes known as community pharmacies, are community-based independent or chain pharmacies. These pharmacies provide the general public with prescription prescriptions, over-the-counter drugs, and health-related products. Retail pharmacies provide convenience for carcinoid syndrome patients who may require home-use medications. Patients can fill their prescriptions and receive continued supplies and support for managing their disease outside the hospital setting at these pharmacies.

The market is sub-segmented into Hospitals, Clinics, and Cancer Research Institutes based on end-users.

Cancer Research Institutes dominate the market growth.

Cancer Research Institutes

The cancer institutions category is expected to attain a significant market share, owing to rising demand for specialized medical care. Cancer research institutes are technical institutions dedicated to improving scientific knowledge, conducting research, and creating novel treatments for various cancers, including unusual illnesses like carcinoid syndrome.

Cancer research institutes also help to advance Carcinoid Syndrome Diarrhea Treatment by conducting clinical trials, understanding the disease's underlying causes, and discovering novel therapeutic approaches. They frequently partner with hospitals and clinics to put study findings into practice.

Hospitals

Hospitals are major medical facilities that offer various medical services such as inpatient care, operations, diagnostic tests, and outpatient treatments. Hospitals serve as essential facilities for comprehensive care, diagnosis, and therapy in the context of Carcinoid Syndrome Diarrhea therapy. Hospitals play an important role in caring for patients with carcinoid syndrome, including specialized medical teams, diagnostic services, and inpatient care. They provide a setting for treating patients with carcinoid syndrome, including chemotherapy and managing their overall health.

Recent Developments

• November 2023- INPEFA® (sotagliflozin) was granted preferred formulary status by Express Scripts for Medicare patients. In December 2023, Novartis will receive FDA approval for Fabhalta® (iptacopan), the first oral monotherapy for adults with PNH that provides superior hemoglobin improvement without transfusions.